Stock Market & Financial Investment News

News Breaks March 5, 2013 16:04 EDT INFI Infinity Pharmaceuticals outlines expected 2013 development milestones Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride (HCl), a potent and selective Hsp90 inhibitor. Infinity anticipates achieving the following development milestones in 2013:2013: Initiate at least two additional trials in patients with hematologic malignancies 2013: Report additional data from ongoing Phase 1 trial in patients with advanced hematologic malignancies 1H2013: Initiate a Phase 2 trial in patients with rheumatoid arthritis 2H2013: Provide update on Phase 2a trial in patients with mild, allergic asthma News For INFI From The Last 14 Days Check below for free stories on INFI the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 07:26 EDT INFI Infinity Pharmaceuticals sell-off excessive, says Wells Fargo Subscribe for More Information May 16, 2013 12:07 EDT INFI Options with increasing implied volatility: INFI WCRX SODA LYV HYG 12:00 EDT INFI Infinity Pharmaceuticals falls 19.5% Subscribe for More Information 07:29 EDT INFI Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. Sign up for a free trial to see the rest of the stories you've been missing.